[ZUG, SWITZERLAND] – [MARCH 21,
2025] – In a groundbreaking achievement, Curetopia,
the first Biotech Decentralized Autonomous Organization (DAO) built natively on
the Solana blockchain, raised $1.77 million last week to scale up drug
repurposing for inherited metabolic diseases through the Bio Protocol Launchpad.
This milestone is driving cutting-edge research aimed at developing the first
treatment for AARS2 Deficiency, a potentially fatal rare genetic disease with
no approved therapies currently on the market. Curetopia’s innovative approach
empowers patients and researchers to crowdfund medical breakthroughs,
emphasizing community involvement and a shared stake in the resulting
advancements. Over 1,000 individual contributors participated in this $1.77
million raise, highlighting the power of community-driven science. Participants
in Curetopia’s decentralized clinical trials become active stakeholders in the
therapies they help to develop. A key outcome of this effort is the
identification of two drug repurposing candidates for AARS2 Deficiency,
uncovered by a fully de-risked, high-throughput, yeast-powered screening
process. Curetopia is filing a provisional patent for this discovery, working
with two pioneer AARS2 families on launching parallel N-of-1 studies, and plans
to reinvest any future proceeds into further research initiatives. Dr. Ethan Perlstein, founder and CEO of Curetopia, stated: “The success of Curetopia’s auction
in the face of brutal market conditions speaks to the fact that rare disease
communities and crypto communities are natural allies. We’ve already
demonstrated with the inaugural AARS2 program that we can deliver results on a
timeline and with capital efficiency that is unheard of in TradBio. Now it’s
time to cook.” Curetopia is part of the growing
Decentralized Science (DeSci) movement, which has collectively raised over $15
million for research in the past three months. This influx of funding is
timely, as traditional sources like the NIH and NSF face ongoing budget
pressures. Moving forward, Curetopia will develop
an AI-driven, decentralized clinical trial model to address thousands of rare
diseases—each representing a $150 million market opportunity based on
historical sales of Priority Review Vouchers. By focusing on drug repurposing,
the organization seeks to expedite regulatory processes and deliver life-changing
treatments to patients more quickly. Curetopia is a non-profit association
pioneering the world’s first Biotech DAO dedicated to eradicating rare diseases
through decentralized science. With over 10,000 rare diseases affecting 1 in 10
people worldwide, Curetopia provides patient communities with innovative tools
to fund research, drive innovation, and ensure promising therapies are not
abandoned. Curetopia, a Biotech DAO,
leverages decentralized science to accelerate rare disease research
About Curetopia
